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ABSTRACT
Title: CLICORADIOLOGICAL OUTCOME IN PATIENTS UNDERGOING LIMB 
SALVAGE OPERATION FOR OSTEOSARCOMA OF THE DISTAL FEMUR AND 
PROXIMAL TIBIA
Department  : Department of Orthopedics Unit II
Candidate     : Dr. Kathir Joyson D R
Degree         : Master of Surgery - Orthopedics
Guide           : Dr. V. T. K. Titus
Objectives: To measure the clinico radiological out come in patients undergoing tumour excision 
and mega-prosthesis for osteosarcoma of the proximal tibia and distal femur in terms of survival 
and local recurrence.
Methods:      Patients who underwent tumour excision and mega-prosthesis for osteosarcoma of the
proximal tibia or distal femur from  January 2010 to October 2014 were included in the study. The 
patients records  were used to finding out the local recurrence, occurrence of metastasis and to 
determine the survival of the patient.  Phone calls were used for patients who had not come for 
follow up.  Data regarding age, sex, value of alkaline phosphatase at diagnosis, time of metastasis, 
time of local recurrence, range of motion Tumor volume, tumour depth,  Blackburne-Peel ratio, 
percentage of resection were collected from the patients records and appropriate imaging.   
Results:  Among our patients the over all survival was 66% and the incidence of local recurrence 
was 20%. Most tumours belong to high grade and had large volume. Tumour volume and tumour 
depth were significantly associated with overall survival. Tumour volume, tumour depth and 
administration of radiotherapy were significantly associated with local recurrence. Tumour volume 
and radiotherapy were independently associated with time to local recurrence. Blackburne-Peel 
ratio was significantly associated decreased lag but the extent of resection of the femur or tibia did 
not have any functional significance. Wound infection was noted in 9 patients and 8 patients 
eventually underwent amputation.
Key words: Local recurrence, Survival, Radiotherapy
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Introduction
3
Osteosarcoma is  the  most  common primary  non-haemopoietic  malignant  tumor  of  the  bone(1).
Though multiple myeloma is the most common malignancy of the bone it is not considered a true
bone tumor.  Osteosarcoma has been recognized for almost two centuries. The term Osteosarcoma
was first coined by Boyer in 1807 to describe the tumors arising from the bone.  It affects manly the
adolescents and young adults and if  untreated it leads to death of the individual. Though it mainly
affects the adolescents there is a second peak in incidence of osteosarcoma among the elderly in
their 7th and 8th decades.  The treatment of Osteosarcoma has changed dramatically over the past
decades. Earlier amputation of the affected limb above the site of lesion was the treatment of choice
due to lack of expertise and instrumentation.  
Over the past decades limb salvage operations are performed with advanced radiotherapy,
chemotherapy  regimens  supporting  the  surgical  treatment.   The  survival  rate  following
Osteosarcoma has dramatically  improved over the years.(2)  But,  despite the modern treatment
protocols and the availability of advanced combination therapy that combine surgery, chemotherapy
and occasionally radiotherapy the survival for Osteosarcoma remains at 58-70%.(1,2) 
Epidemiology of Osteosarcoma:
Incidence:
Osteosarcoma is very rare in children who are less than five years of age. A bimodal age
distribution  is  seen  with  a  primary  peak  among  adolescents  and  young  adults(<25  years)
constituting  about  53% of  those  with  Osteosarcoma  with  most  of  the  osteosarcoma  occurring
between the age group of 10-25 years.  There incidence of Osteosarcoma was lower in the age
group of 25 to 59 years.  There was a secondary peak among the people belonging to the age group
60 years and above. (3)
 As  we  move  the  age  group  over  60  years  only  13-30%  constitute  the  patients  with
Osteosarcoma.  The incidence of Osteosarcoma is slightly more in males than in females.  The
4
overall male to female including all the age groups was 1.22:1.  But among the patients below 15
years of age more girls were affected than the boys.  There peak incidence was found to be earlier
among the girls. Being 12 years, when compared with 16 years in boys.(3)
Source:Savage SA, Mirabello L. Using Epidemiology and Genomics to Understand Osteosarcoma Etiology. Sarcoma. 2011 Mar 8;2011:e548151. (4)
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Source:Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004. Cancer. 
2009;115(7):1531–43.
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Anatomical site and location:
Osteosarcoma usually arises in the metaphysis of long bone inside the medullary cavity. It
then penetrates the cortex of the bone. After breaching the cortex it then involves the soft tissue
around the metaphyseal region. As the tumour grows a pseudo-capsule is formed around the tumour
which aggressively penetrates into the soft tissue.  Though Osteosarcoma can occur in any bone it
most commonly occurs in the long bones near the metaphyseal growth plate of the appedicular
skeleton.
Most  of  the  Osteosarcoma  originate  around  the  knee  accounting  for  about  60% of  the
Osteosarcoma occurring in humans. In femur it affects the distal femur in 75% of the individuals
with Osteosarcoma of the femur. While in tibia, 80% of the time it originates in the proximal tibia.
The humerus constitutes to about 10% of the Osteosarcoma with 90% of them originating in the
proximal humerus.(5)
Among the Osteosarcoma which originate in the long bone 90%  occur in the metaphyseal
region, 9% in the diaphyseal region and  very rarely in the epiphyseal region.(6) But as we look
separately at the patients above 60 years of age the axial skeleton was the most commonly affected
(27%), in addition to the craniofacial bones (13%) and extra skeletal sites (11%).(7) Compared to
the younger population where Osteosarcoma occurs more in the sites of rapid growth such as the
metaphyseal region only 14.5% of the older patients with Osteosarcoma had the tumor originating
from such sites.(7)
 
Bone Percentage(5)
Femur 42%
Tibia 19%
Humerus 10%
Skull and jaw 8%
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Pelvis 8%
Etiological associations of Osteosarcoma:
Environmental exposures:
Exposure to radiation has been associated with increased risk of Osteosarcoma. The patient
who have undergone treatment  with radium for conditions  such as ankylosing spondylitis  were
found to be at  increased risk of bone sarcomas.(8) Survivors of Hodgkins lymphoma who had
undergone radiation as a part of treatment were also found to be at higher risk of Osteosarcoma.(9)
Varying results have been obtained when comparing exposure to fluoride and its association
with Osteosarcoma. It was found that there was an association between fluoride levels in drinking
water in childhood and incidence of Osteosarcoma. This association was only noticed in males.(10)
This  finding  was  not  consistent  among  females.  Other  studies  have  shown  that  there  is  no
association  between  fluoride  exposure  and  Osteosarcoma.(11) Radium  in  drinking  water  was
associated with increased risk of Osteosarcoma among youth.(12) Radium dial  painters are also
found to have increased incidence of Osteosarcoma.(13)
Growth:
Osteosarcoma has been found to have an increased incidence in the pubertal age group. It is
a age group when the remodeling of bone and bone growth is very active. Various hormones have
been found to be at increased levels and play a role in this stage. At puberty the levels of insulin-like
growth factor 1(IGF1), sex hormones, and growth hormones are found to be high. Insulin lie growth
factors have been implicated as possible agents in the development of Osteosarcoma.(14) In patients
with  acromegaly  there  have  been  case  reports  of  Osteosarcoma.(15) Though  the  incidence  of
Osteosarcoma has not been quantified among patient with acromegaly its been hypothesized that
prolonged exposure  to  growth hormone may play  a  role.   Single  nucleotide  polymorphisms of
IGF2R have also been associated with increased risk of Osteosarcoma.(16)
Height:
Height has been counted as a risk factor for Osteosarcoma. Some studies have shown as
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association and other have not.  The largest cohort of patients with Osteosarcoma studied showed
that the patients under 18 years who had Osteosarcoma were taller that normal.(17) Another meta-
analysis showed an association between height at diagnosis and Osteosarcoma.(18)  It is thought
that children having faster growth spurts during puberty are exposed to higher levels of the growth
hormones and factors probably leading to a increased risk of developing Osteosarcoma. 
Birth weight:
Varied  results  have  been  published  about  the  association  between  birth  weight  and
Osteosarcoma.  Higher  birth-weight  has  also  been  associated,  thought  weakly,  with  increased
incidence of Osteosarcoma. A recent meta-analysis done showed children with birth-weight more
that 4046g having an elevated risk of Osteosarcoma.(18) It has been postulated that birth weight
may have a role by its association with intrauterine growth factor levels that the baby is exposed to.
Pagets disease:
Pagets disease has also been considered as one of the risk factors for Osteosarcoma. Though
the exact incidence has not been elucidated the incidence of Osteosarcoma among patient  with
Pagets  disease  is  thought  to  be  <1%.(19) Though  the  association  and  the  reason  behind  the
increased incidence is not well explained the outcome for these patients who develop osteosarcoma
remains bleak.
Genetic factors:
The presence of chromosomal aneuploidy in osteosarcoma indicates the possible role played
by chromosomal  instability  in  putting  a  patient  at  risk  of  osteosarcoma.  Thought  studies  have
elaborated on the possible role of chromosomal instability, no single consistent definite association
has been found between any specific changes so far.  Single nuclear polymorphisms of  Tumor
Necrosis Factor-α (TNF), Vitamin D Receptor (VDR), Estrogen Receptor (ESR1), Collagen 1α1
(COL1A1), Tumor Protein p53 (TP53), Insulin-like Growth Factor 2 Receptor (IGF2R), Fas (TNF
receptor  super-family,  member  6;  FAS),  Mdm2  p53  binding  protein  homo-log  (MDM2),
9
Transforming growth factor beta receptor 1 (TGFBR1) and 8q24 region have been studied and have
been  associated with a increased risk of developing osteosarcoma. 
Moreover various syndromes have been associated with the increased risk of Osteosarcoma.
Though they are rare they help us in understanding the disease more. Table illustrates the various
syndromes that have been associated with Osteosarcoma. Li-fraumeni  Syndrome is  caused  by  a
germ-line mutation in the TP 53 gene which encodes for p53 protein. This protein has been found to
be of  importance in DNA repair, normal cell growth and various other mechanisms of the cell. 
Retinoblastoma is caused by mutations in the RB1 tumor suppressor gens. Among patients
with Retinoblastoma, Osteosarcoma is the second most common tumour. It has been shown that
patient with hereditary retinoblastoma are at a higher risk of osteosarcoma than those with sporadic
retinoblastoma.  (20)  The  children  with  this  gene  mutations  are  at  high  risk  for  developing
retinoblastoma and usually present at an age of than 5 years.
Blooms syndrome is caused by mutation in the BLM helicase gene. Though the incidence of
Osteosarcoma is not very high in these patients it is still higher than the general population.
Werner's  syndrome is  associated  with  an increase  risk of  osteosarcoma.  It  is  caused by
mutations in the WRN DNA helicase gene. The patients typically are describe to have short stature,
bird facies,  parental  history of consanguinity, atrophic skin,  premature atherosclerosis  and early
cataracts.
Diamond Blackfan Anemia is an inherited disorder where the patient presents with inherited
red cell aplasia. Identifiable mutations in the gene important for ribosomal functions are found in
around 40% of patients.  Though the involvement of these mutations is not fully understood the
increased incidence of osteosarcoma among these patients is notable.
Disorder Chromosome Gene Inheritance pattern
Li-Fraumeni Syndrome 17p13.1 TP53 Dominant
Rothmund Thomson syndrome 8q24.3 REQL4 Recessive
Retinoblastoma 13q14.2 RB1 Dominant
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Bloom Syndrome 15q261 BLM Recessive
Diamond Blackfan Amnemia Multiple RPS19,  RPL5,
RPL11,RPL35A,  RPS24,
RPS17,RPS7
Dominant
Werner Syndrome 8p12 WRN Recessive
Pathogenesis of Osteosarcoma:
As mentioned above bone growth, various environmental factors, genetic factors etc. have
been shown to play a role in the pathogenesis of Osteosarcoma. There factors play a role at the
molecular level leading to rapid tumour growth and metastasis.
Growth factors:
Osteosarcoma cells produces a variety of growth factors. These factors have their autocrine
and paracrine  effects  on the cells.   Moreover  there is  dis-regulated  expression of these growth
factors and  there is also a over activated signal transduction associated with these receptors.
Some growth factors that have been implicated are transforming growth factor, insulin-like
growth  factor  and  connective  tissue  growth  factor.  This  leads  to  rapid  proliferation  of  cells.
Parathyroid  hormone  and  parathyroid  hormone  related  peptide  and  the  receptor  have  been
associated with Osteosarcoma metastasis and progression. It was found that there was increased
proliferation, invasion through Matrigel and increased motility when the Osteosarcoma cells were
over expressed with parathyroid hormone related peptide 1. 
Failure of apoptosis:
Apoptosis plays an important role in the death of the cells that turn rogue. Cancer cells find
ways to circumvent pathways that bring about apoptosis and avoid their elimination. Hence they
proliferate without any restriction. Apoptosis has two steps which are initiation and execution. In
the initiation phase Capsases are activation and in the execution phase these activated capsases
execute the actual process of hydrolysis and cell death. The cells that are no longer attached to a
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basement membrane or a matrix undergo apoptosis under normal circumstances. This process is
termed as Anoikis.  It has been shown that Osteosarcoma cells are anoikis resistant and in-spite of
the deranged cell-cell and cell matrix attachments they proliferate, which is termed as anchorage
independent growth. The picture below summarizes the various pathways that disrupt anoikis. 
Tumour  angiogenesis:
The tumour tissue is in a pro-angiogenic state due to the acidotic micro-environment, tissue
hypoxia,  loss  of  tumour  suppressor  gene  function,  oncogene  activation.  There  is  also  down
regulation of the anti-angiogenic factors such as thrombospondin 1, TGF-β, troponin I, pigment
epithelial-derived factor etc. The Von Hippel lindau protein releases hypoxia inducible factor–1a
which then binds to vascular endothelial growth factor gene and then up-regulates it. This leads to
stimulation of the endothelial cell proliferation, migration and blood vessel maturation.  Moreover
vasodialation  and  increased  vascular  permeability  is  caused  by  nitric  oxide  released  by  the
endothelial  cells.  Eventually  with  the  involvement  of  various  intermediate  factors  a  immature,
irregular and leaky vascular network results.
12
Broadhead ML, Clark JCM, Myers DE, Dass CR, Choong PFM. The Molecular Pathogenesis of Osteosarcoma: A Review. Sarcoma. 2011;2011:1–12. 
Cell migration:
Osteosarcoma has a very high metastatic potential. This requires the Osteosarcoma cells to
detach from the area of the tumour, then adhere to the extracellular matrix. Following adhesion to
the extracellular  matrix  the cell  goes through local  migration  and invasion through the stroma,
intravasation and extravasation. The complex cell to cell and cell to matrix interactions that occur
facilitates  this  process.  The  various  proteins  involved  in  this  process  include  those  in  the
extracellular  matrix  such  as  fibronectin,  proteoglycans,  laminins,  collagen  and  those  receptor
proteins in the cell surface such as the integrins. The interactions between the proteins of the tumour
cells   and the extracellular matrix causes conformational  changes in the architecture of the cell
leading to the formation of membrane ruffles. These changes help in cell migration and metastasis. 
Invasion of the tumour cells and destruction of bone matrix:
Degradation of the extracellular matrix is essential for the osteosarcoma to invade into the
surrounding tissues. This is facilitated by the family of  Matrix metalloproteinases which include
stromeolysins, gelatinases and collagenases. These matrix metalloproteinases clear the pathway for
the  cells  to  grow  into  the  surrounding  tissues.  Moreover  the  matrix  metalloproteinases   also
facilitate  angiogenesis.  While  acting  on  the  extracellular  matrix  the  matrix  metalloproteinases
release  Vascular  endothelial  growth  factor  which  in-turn  further  up-regulates  the  matrix
metalloproteinases.  Another  pathway which  plays  a  role  in  osteosarcoma invasion  is  urokinase
plasminogen activator system. In this pathway plasminogen is broken down to plasmin which then
breaks  down  the  extracellular  matrix  and  also  leads  to  further  activation  of  the  pro-matrix
metalloproteinases. Hence a cascade of activation is established.(21,22)
The  invasion  of  the  osteosarcoma  cells  also  depends  on  the  interactions  between
osteosarcoma cells, osteoclasts, and the matrix of the bone.  The degraded bone matrix releases
transforming growth factor-β which then stimulates the osteosarcoma cells to release parathyroid
hormone-related peptide, interleukin-11 and interleukin-6. The osteoclasts are stimulated by these
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cytokines  released  by  the  osteosarcoma  cells  in  turn  stimulates  the  osteoclasts  to  release  pro-
resorptive cytokines which leads to further invasion. The osteoblasts also function as mediators in
bone resorption by the increased  receptor activator of nuclear factor κB ligand expression which in
turn activates the osteoclasts which in-turn released proteases which resorb the unmineralized part
of bone. One among the proteases is Cathepsin K and its been found that patients with low levels of
Cathepsin K at diagnosis have better prognosis. (23)
 Receptor  activator  of  nuclear  factor  κB ligand  plays  a  central  role  in  the  activation  of
osteoclasts and invasion of bone. Osteoprotegerin a decoy receptor for  receptor activator of nuclear
factor κB ligand if found to suppress the differentiation of osteoclasts.  In rodent models it was
shown that osteoprotegerin gene transfer  prevented the formation of osteolytic lesions, decreased
tumour incidence, decreased tumour growth and increased survival.(24) 
The following picture explains this complex interactions that occur leading to invasion of
the Osteosarcoma cell and metastasis.
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Broadhead ML, Clark JCM, Myers DE, Dass CR, Choong PFM. The Molecular Pathogenesis of Osteosarcoma: A Review. Sarcoma. 2011;2011:1–12. 
Histopathology:
Osteosarcoma is named so because of the presence of osteoid or the ability of the tumour
cells to produce osteoid. Though the name Osteosarcoma gives a implication for the tumour to be of
osteblastic origin there is no evidence for the same. This is implied well in the term osteogenic
sarcoma, a terminology used earlier  to describe Osteosarcoma.  It is also noted that the tumour
produces variable quantities of fibrous tissue and cartilage matrix. The proportion of the cartilage
matrix,  osteoid,  fibrous tissue sometimes vary significantly that  it  might  be difficult  to  make a
diagnosis of Osteosarcoma. It has also been seen that osteosarcoma produce different amounts of
matrix which might be cartilage or fibrous tissue. Sometimes the fibrous tissue or the cartilage may
be in  such high  proportion  that  it  might  be  needed to  seek  out  the  osteoid  matrix  to  make  a
diagnosis of Osteosarcoma. 
Traditionally osteosarcoma have been subdivided into three types
1. Osteoblastic
2. Fibroblastic
3. Chondroblastic
Though the classification into any of these types is arbitrary it generally signifies at-least a 50%
predominance  of  the  particular  histological  type.  Based  on  the  site  of  origin  they  can  be
intramedullary, surface osteosarcoma or extra-skeletal.  Intramedullary tumour are generally high
grade and surface osteosarcoma are generally low grade.
Sometimes the tumour can have high grade and low grade components in the same tumour and in
such a case the tumour generally behaves similar to the higher grade of sarcoma present among the
tumour contents.
Osteosarcoma can be classified based on the anatomical location of the tumour or the pathology of
the tumour.  
15
The following tables classifies them based on the anatomical location of the tumour. (25)
Classification of Osteosarcoma based on anatomical location
Osseous Surface
Gnathic
Central
Multi-focal
Soft tissue Intramuscular
Other
The following table classifies Osteosarcoma based on the histopathology of the tumour.(25)
Types of Osteosarcoma
Central High grade Conventional
Telangiectatic
Small cell
Epithelioid
Osteoblastoma-like
Chondroblastoma-like
Chondroblastoma-like
Fibrohistiocytic
Giant cell-rich
Low-grade Desmoplastc fibroma -like
Fibrous dysplasia - like
Surface High-grade De-differentiated parosteal
High-grade surface
Intermediate-grade Periosteal
Low-grade Parosteal
Gnathic
Intra cortical
Extra-skeletal High-grade
Low-grade
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Histological grading of Osteosarcoma:
The  histological  grading  of  Osteosarcoma  is  based  on  the  grading  of  squamous  cell
carcinoma of the lip as described by Broders  et al.(26)  In this grading the tumors are graded in a
scale based on the amount of anaplasia in the tumour.  In this grading system it is assumed that
cytological atypia is the most important factor that determines the grade of the tumour.  Hence any
area of significant anaplasia will switch the tumour to a higher grade of 4. 
The problem with this grading system arises when there is a normalization effect seen as in
sclerosing osteosarcoma.
Histological grading of Osteosarcoma
Grade Percentage of anaplasia
Grade I <25%
Grad II 25-50%
Grade III 50-75%
Grade IV 75%-100%
In clinical practice conventional osteosarcoma usually fall under either a grade 3 or 4 and
hence they are considered high grace and surface osteosarcoma are low grade. Hence usually for
most practical purposes there are two tiers of grading ie. High-grade and low grade.  When the
tumour does not fit  into either a high-grade or a low-grade then a third tier  is added and it  is
classified as an intermediate grade tumour.
Conventional Osteosarcoma:
This is the classic form of Osteosarcoma and they are easily diagnosed where they
are in their classic form.  Mitotic cells are easily seen with the presence of atypical mitotic cells.
The cells may be polyhedral or spindle shaped and with a hyper-chromatic pleomorphic nuclei.  The
cells  also  produce  osseous,  fibrous  or  cartilaginous  matrix  in  varying  proportions.   Though
conventional osteosarcoma have been divided as osteoblastic, chondroblastic and fibroblastic there
is  no statistical  difference  in  the survival  rates  of  the patients  with high-grade tumors  of  these
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different sub-types.
In the purely sclerosing Osteosarcoma the tumour cells get incorporated into the bone matrix
and hence it is difficult to identify the cellular component. But the cellular component can be easily
visualized at the advancing edge of the tumour.  In some patients with sclerosing osteosarcoma the
bone matrix grows  between the adipocytes along the interseptal spaces. This may appear as if the
lesion  is  non  malignant.  In  such  cases  clinico-radiological  correlation  will  help  to  clinch  the
diagnosis.  Moreover there would be microscopic  soft  tissue involvement  that  would be evident
though the gross section may appear uninvolved.
18
Source : N F, Lc M. Primary malignant giant cell tumour of the proximal tibia: a case report. Journal of Cancer Research & Therapy. 2013 
Aug 1;1(6):174–7. 
Telangiectatic Osteosarcoma:
This is a type of osteosarcoma which resembles aneurysmal bone cyst both radio-graphically
and histologically. It  produces  a  asymmetric  expansile  lesion  with associated  radio-lucent  bone
destruction.   Interrupted  periosteal  reaction  is  seen  and  since  there  is  little  bone  formation
conventional radiographs may not show bone formation. With the advent of computed tomography
some  bone  matrix  is  detected  in  at-least  85%  of  the  telangiectatic  osteosarcoma.  Magnetic
resonance imaging of the tumour shows blood filled sinusoids which are multiple in number with
little soft tissue content. Though on a low power microscopic evaluation it appears as much as an
aneurysmal  bone  cyst,  the  high  mitotic  rate  and  the  presence  of  pleomorphic  nuclei  helps  to
differentiate the two. Moreover there is local destruction and permeation into the cortical haversian
canal or the adjacent marrow.(25)
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     Source: Mahdi Y, Rouas L, Amrani A, Malihy A, Lamalmi N, Alhamany Z. Neglected telangiectatic osteosarcoma of the femur presenting as surgical 
emergency. International Journal of Case Reports and Images. 2014;5(5):391. 
It has also been noted that telangiectatic osteosarcoma have foci of osteoclastic giant cells.
Earlier  it  was  found  that  outcome  for  telangiectatic  osteosarcoma  was  poor  compared  to  the
conventional osteosarcoma. With the advent of Chemotherapy this has changed and outcomes for
telengiectatic osteosarcoma are considered equivalent or better compared to osteosarcoma.
Small cell Osteosarcoma:
It is rare variant of osteosarcoma constituting about 1-2% of all osteosarcoma. Though this
tumour resembles Ewing's sarcomas in its immunological profile by the positivity of CD 99, it
differs by the production of osteoid.  Histologically it resembles Ewing's sarcoma by the presence of
small round cell with hyper-chromatic nuclei. The nuclear pleomorphism in small cell osteosarcoma
is much less compared to conventional osteosarcoma. The reciprocal  trans-location between the
chromosomes 11 and 22 most commonly reported in Ewing's sarcoma has also been occasionally
reported  in  Small  cell  Osteosarcoma.  All  this  similarity  with  Ewing's  sarcoma  makes  it  a
controversial diagnosis with some authors contenting to consider them as Ewing sarcoma/PNET.
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Epithelioid Osteosarcoma:
Epithelioid osteosarcoma are called so due to the difficulty in differentiating whether the
tumour is a sarcoma or carcinoma.  The diagnosis becomes difficult especially when there is little
osteoid  productions  and  the  tumour  cells  resemble  epithelial  cells.  There  may  be  gland  like
structures and the cells may be arranged as papillary structures. When these tumors are seen in the
younger  age  group  osteosarcoma  must  be  considered.   In  case  of  older  patients  metastatic
carcinoma  must  be  considered.  Immuno-histochemical  analysis  might  be  positive  for  keratins
though the tumour may be an osteosarcoma.  Hence a careful  search must be made for osteoid
formation especially in younger age group.
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Source: http://www.orthopaedicsone.com/display/PORT/Epithelioid+Sarcoma
Kyoji  et  al.  described  subtype  of  rosette  forming  epithelioid  osteosarcoma  with  very
aggressive clinical behavior.(27)
Giant cell rich Osteosarcoma:
Giant  cells  have  been  noted  in  as  many  as  25% of  all  osteosarcoma.   Sometimes  the
presence of giant cell make diagnosis difficulty especially in areas where giant cell tumour is more
common that Osteosarcoma, such as the sacrum. But giant cell tumors arises in skeletally mature
people.  Moreover periosteal reaction is generally absent in giant cell tumour the exception being a
associated pathological fracture.   Hence the presence of a giant cell  rich lesion with associated
periosteal reaction in a immature skeleton must be carefully evaluated to rule out the presence of
osteosarcoma.
Gnathic Osteosarcoma:
The osteosarcoma of  the  mandible  and maxilla  usually  present  with  pain  and swelling.
Conventional  radiographs  show radio-lucent  area  or  a  mixture  of  radio-dense  and  radio-lucent
areas. They are predominantly chondroblastic osteosarcoma. But other types such as osteoblastic,
fibroblastic and small cell osteosarcoma have been reported. They are usually high-grade tumors
and leads to uncontrolled local  disease.  Osteosarcoma occurring in the other craniofacial  bones
generally occur among the older age group and is usually associated with conditions such as Pagets
disease, past exposure to radiation etc.
Chondroblastoma like and osteoblastoma like osteosarcoma:
Osteoblastoma like  osteosarcoma appears  similar  to  osteoblastoma by producing similar
microtrabecular  bone  which  are  lined  by  osteoblasts.  But  radiologic  appearance  can  help  to
differentiate a malignant tumour.  But this differentiation may be absent as osteoblastoma can have
atypical radiological appearance. Some times osteoblastoma may also contains atypical cells and
this makes differentiating a malignant lesion from a benign lesion extremely difficult. The presence
of aneuploid mitotic activity and permeation of the normal bone at the tumour bone interface helps
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to differentiate a malignant lesion. 
Chondroblastoma  like  osteosarcoma  is  a  very  rare  tumour.  It  may  be  present  in  the
epiphyseal region. The presence of the tumour in the epiphysis makes diagnosis very difficult as the
features  cannot  be  distinguished  exclusively.  But  the  presence  of  osteoid,  atypical  cell  and
permeation of the trabeculae helps to differentiate from the benign counterpart.
Low grade Central Osteosarcoma:
Low  grade  central  osteosarcoma  are  quite  uncommon  compared  to  the  high  grade
counterpart.   The  osteoid  formation  is  scant  and  it  has  a  bland  fibrous  stroma  contained  the
microtrabecular  bony matrix.  Though they mimic  benign  lesions  such  as  fibrous  dysplasia  the
presence of dense sclerosis, indistinct zone of transition, interrupted periosteal reaction and cortical
infarction helps us to differentiate from them. Sections of the interface between the tumour and the
normal bone shows fibrous tissue inside the haversian canals and between the mature trabecular
bone and this confirms it as a malignancy.  Though these lesions have good outcome with surgical
treatment  alone  it  has been reported  that  some of the patients  developed secondary high-grade
osteosarcoma at the same site.
Surface osteosarcoma:
They are osteosarcoma whose epicenters are away for the underlying cortex.  They arise
from the cortex of the bone or the periosteum without involving the medullary cavity or involving
the medullary  cavity minimally. There occur  in the third or the fourth decade compared to  the
conventional osteosarcoma which occur in adolescence. They are predominantly low grade tumours
with low risk of distant metastasis. But they have a propensity towards local recurrence.  Around
10% of the surface osteosarcoma are high grade in nature.  
Parosteal osteosarcoma:
This is the most common form of surface osteosarcoma. It accounts for less that 1 out of 20
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osteosarcoma that are diagnosed. It was first described by Geschicter and Copeland. Its incidence is
around a decade after the age group for conventional osteosarcoma. About 75-80% of the parosteal
osteosarcoma  arise  from  the  distal  posterior  femur.  It  usually  presents  as  a  fullness  over  the
popliteal  region or it might restrict  full flexion. Conventional radiographs show a lesion of non
uniform radio-density, being more radio-dense  centrally  than  peripherally  and the lesion is  not
continuous with adjacent cortex nor the medullary cavity thus differentiating from osteochondroma.
On  radiographs  a  thin  radio-lucent  line  separates  the  tumour  from  the  adjacent  cortex.  When
resected and examined this correlates with the periosteum of the bone and the tumour is attached to
the periosteum at some point. Periosteal reaction is absent as this tumour does not lift the cambium
layer off the cortex. Histological examination shows steamers of trabecular bone which are arranged
in  parallel  orientation  similar  to  a  periosteal  new  bone  formation.  Mira  et  al.  described  this
appearance a a flowing steel wool appearance. About 25-30% of the cases have a cellular cartilage
cap outside the bony portion of the lesion. Most of the parosteal osteosarcoma are associated with
outer fibrous layer of the periosteum and hence they do not produce typical periosteal reactions.
Sometimes these tumors may break through the periosteum and the cortex though it might be low
grade. But it has been noted that invasion of the cortex does not worsen the prognosis  as long the
tumor is low grade in nature.
Periosteal Osteosarcoma:
This is a intermediate grade osteosarcoma  first describe by Unni et al.(28) The incidence of
this tumour is much less common compared to the parosteal osteosarcoma. It arises between the
cambium layer  and the bony cortex and hence is associated with vivid periosteal reaction.  The
underlying cortex is either thickened or eroded but it never extends into the endosteum.
Dedifferentiated parosteal osteosarcoma:
It was first described by Wold et al.(29)  Though following the first series that was published
it  was  thought  that  the  tumour  occurs  as  a  recurrent  disease  following  a  previous  low-grade
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parosteal osteosarcoma, it  is now considered that these dedifferentiated areas are present in the
initial  resection  of  parosteal  osteosarcoma  itself.   This  dedifferentiated  area  can  be  grossly
distinguished from the sclerotic ares of the parosteal osteosarcoma. Histologically it contains areas
of low grade parosteal osteosarcoma and high-grade parosteal osteosarcoma. Though the prognosis
is poorer than typical parosteal osteosarcoma it is better than high-grade parosteal osteosarcoma.
Bertoni  et  al  reported  that  this  dedifferentiation  occurs  in  one  in  four  cases  of  parosteal
osteosarcoma.(30)
High-grade parosteal osteosarcoma:
This is a surface bone lesion and it has a histological high-grade. Radio-graphic appearance may
vary from features  of parosteal  osteosarcoma to mixed features  or presence of large soft  tissue
component.  Its  has  a  accelerated  growth  compared  to  parosteal  osteosarcoma  and  it  is  more
aggressive. CT and MRI may show foci of marrow infiltration occasionally. It is differentiated from
a conventional  osteosarcoma  by it  having  a  epicenter  outside  the  bone and  by the  absence  of
periosteal reaction.
Intra-cortical osteosarcoma:
This is a very rare variant of Osteosarcoma described by Jaffe et al.  and it occurs as a area of
lucency within the bony cortex with surrounding sclerosis.(31,32)  Abundant osteoid formation is
present histologically. It behaves like a conventional osteosarcoma and hence it must be treated
aggressively.   The  other  lesions  that  may  be  confused  with  this  are  osteoid  osteoma  or  a
osteoblastoma.
Multi-focal osteosarcoma:
This  is  a  very rare  condition which affects  multiple  bone either  at  the same time or at
varying intervals. Based on this they can be 
1. Synchronous 
2. Metachronous 
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The synchronous form generally occurs in children, being symmetric and radio-dense, it is
quickly fatal. The metachronous form, being asymmetric with variable sclerosis generally occurs in
adults with varying disease free intervals. Though metastases is a differential diagnosis the longer
survival associated with the patients speak that these are a different class of tumors.
Extra-skeletal osteosarcoma:
It accounts for less than 2% of soft tissue sarcomas. It occurs in the 5h to 7th decade and it arises in
the deep soft tissues mainly in the arm, buttock and in the retro-peritoneal region. Radiographs
show mineralization of the tumour and it can be better appreciated on a computed tomograph. All
histological types can occur and the prognosis depends mainly on the grade of the tumour. High
grade tumors have high mortality while low grade tumour though rare have better survival rates. 
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Clinical features:
Most patients with osteosarcoma present with localized pain which lasts for several months.
The most common sites involved are the distal femur, proximal tibia, proximal humerus, proximal
femur followed by other regions. They generally do not have any fever, weight loss, malaise or any
other  systemic  symptoms.  Widhe  et  al.  found  that  87%  of  the  patients  presented  with  pain
associated with strain. Intermittent pain at rest was also common. But only 21% of the patients with
osteosarcoma had night cries. 47% of the Osteosarcoma had history of trauma at the onset of the
symptoms and 58% of male patients and 35%of female patients were involved in sports. (33)
Among the patients regional pain alone  was the main complaint that brought the patients to
the hospital in 70% of the patients and pain and palpable mass were the initial complaints in 25% of
the patients. 
Angela et al. noted that 78% of the patients had pain, 62% had difficulty in walking, 50%
had swelling, 38% had edema, 10% had warmth and 8% had erythema. (34)
The most  important  finding  on clinical  examination  is  a  palpable  mass  with  associated
tenderness which arises from the bone. There might be associate compression of the vessels and
nerves  depending on the  size  of  the  mass.  Pathological  fractures  can  also  be present  at  initial
presentation. Angela et al. found that 42% of the patients had pathological fractures at presentation.
Widhe  et  al.  showed that  the  following physical  findings  were  present  at  the  first  visit
among the 102 patients with Osteosarcoma he studied.
Physical findings at the first visit(33)
Local tenderness  92%
Painful joint movement 39%
Mass on palpation 39%
Movement restriction of the joint 23%
Limp while walking 31%
Muscle atrophy 5%
Fever 3%
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About 10-20% of the patients  with osteosarcoma have demonstrable  macro-metastasis  at
presentation. Though these metastases most commonly involve the lung, bone involvement is also
noted.
Investigations:
Various modalities of investigations are used  to diagnose and stage osteosarcoma. They are
detailed as below.
According  to  the  appropriateness  criteria  of  American  College  of  Radiology  plain
radiographs must be the initial modality of evaluation for a bone lesion. They are inexpensive and
features noted on the plain radiographs help in the diagnosis of the lesion. Moreover they also help
to decide on the need for further evaluation and imaging. 
Osteosarcoma  shows  features  of  a  aggressive  lesions  such  as  wider  zone  of  transition,
cortical destruction, periosteal new bone formation and associated soft tissue mass. The periosteal
reaction is typically described as codman's triangle or sunburst appearance, hair on end appearance
etc.  Osteolysis is more of a feature of the telangiectatic osteosarcoma and sclerosis is more seen in
the sclerosing type.  In patients in whom the physis is still active it generally acts as a barrier but
aggressive tumors can cross the physis. 
But lytic lesions will not be detected on the plain radiographs until 30-50% demineralization
of the bone. If the radiographs are normal and the patient persists to have symptoms then he must be
evaluated with further imaging. The most preferred imaging in such a setting is a MRI as it detects
marrow lesions much better than other modalities. Moreover it also helps to know whether if there
are any other modalities apart from the bone. MRI though expensive is preferred because of its
superior  soft  tissue  definition,  demarcation  of  the  neurovascular  bundle,  marrow  and  joint
involvement and the presence of skip lesions.(35)  MRI has also been used to predict the effect of
neoadjuvant chemotherapy as it detects  the decreased neo-angiogenesis following chemotherapy.
(36)   
28
29
Osteosarcoma of the distal femur with Pathological fracture AP/Lateral views
Another study showed that diffusion weighted imaging is a good non-invasive predictor of
the response to neoadjuvant chemotherapy as it detects the early changes in the cells following
chemotherapy.(37)  Some proponents of diffusion weighted imaging advocate the usage of  it as a
surrogate marker for estimating the response the chemotherapy.  
Gillespy el al concluded that MRI is extremely accurate in measuring the intramedullary
extent of osteosarcoma.(38)    Schima et al. showed MRI is extremely accurate in predicting joint
involvement.(39)
If the patient  has pain that cannot  be localized the bone scan would be a better  option.
Technitium 99m diphosphate is administered at a dose of  20mCi and the scan is done in three
phases:  the  flow phase,  blood pool  phase  and the delayed phase.   The flow phase images  are
obtained one minute after the injection of Tc99m diphosphate and blood pool phase is obtained at 5
min after injection.  The delayed phase is obtained 2-4 hours after injection of Tc99m diphosphate.
The  flow  phase  illustrates  increased  blood  flow  to  a  area,  the  blood  pool  phase  illustrated  a
increased blood pooling in a area by capillary leakage etc and bone images are obtained in the
delayed phase.
Chest X ray helps to pick up the presence of metastasis  and the it is typically described as
canon ball like lesions.  More over bone scan would be needed to stage the disease and rule out any
distant metastases. The patient also needs spiral computed tomography of the thorax to rule out
metastatic lesions of the lung.
  PET/CT scanning has been evaluated for its  use in tumour detection,  grading, tumour
staging, monitoring following therapy, prognostication and as guide for obtaining biopsy. In this a
positron emitter  which is preferentially  taken up by tumor tissue is used.   F18-deoxyglucose is
injected into the patient which is taken up by tumour tissue.  Dual photons are released following
the annihilation reaction between the positron released from F18-deoxyglucose  and an electron.
These dual proton events are detected by the detectors which are placed around the patient. (40,41)
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But it has been found that though PET/CT can be helpful in the above mentioned situation,
it is less cost effective and provides very little additional information most of the time. Histological
examination is the gold standard for obtaining tumour grade, tumour staging is best done using a
conventional  CT to  avoid  the  false  positive  provided  by  PET/CT.  PET/CT might  have  some
usefulness  in  patients  with  non-pulmonary  metastases  and  for  monitoring  response  following
therapy. But it needs further research and standardization before it becomes the standard of care.
The following table summarizes the pros and cons of PET/CT.(40)
Pros and cons for PET/CT
Pros Cons
Allows biopsy guidance to active metabolic areas
Clinical  suspicion  of  aggressive-appearing
lesions directs physicians to re-sample equivocal
biopsy Results
Allows  evaluation  of  chemotherapy  response
before resection and histologic examination
Cutoffs  for  stopping  chemotherapy  by  PET/CT
are poorly defined
Allows for evaluation of lymph nodes and non-
pulmonary sites of metastatic disease
PET/CT  has  false-positives  that  cause
unnecessary  biopsies  and  procedures  to  be
performed
Allows for noninvasive grading of tumors PET/CT does  not  obviate  biopsy,  which  is  thegold standard for tumor grading
As per the ESMO Guidelines Working Group the following are considered as requirements
for the diagnostic work-up of patients with Osteosarcoma.
Diagnostic work-up for osteosarcoma patients(42)
Primary tumor
Plain radiographs
Tumor  localization  in  two  planes  -  whole
extremity p/a
Magnetic resonance imaging Metastases Whole extremity/tumor region
99mTc bone scan Whole skeleton
Computed tomography Chest
Organ function
Heart Echo-cardiogram, electrocardiogram
Hearing Audiogram
Kidney Creatinine (including estimated clearance)
Tubular function tests
Liver Liver function tests
Other laboratory
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Alkaline phosphatase in serum
Lactate dehydrogenase in serum
 
Alkaline  phosphatase  is  found  to  be  increased  in  some  patients  with  patient  with
osteosarcoma.  One study which included 560 patients with high-grade osteosarcoma noted that
alkaline phosphatase was normal in 54% of the patients with osteosarcoma  and it was high in 46%.
(43)  Some studies have shown that the level of alkaline phosphatase at diagnosis has prognostic
significance with higher levels alkaline phosphatase having poorer outcomes.(43,44)  Another study
noted a positive correlation between decrease in bone alkaline phosphatase and the response to
chemotherapy.(45)
The patient  also  needs  investigation  to  evaluate  his  fitness  for  neoadjuvant  or  adjuvant
chemotherapy and also for a baseline recording of his heart, ear and renal functions before starting
chemotherapy.
Biopsy:
Biopsy is most essential for diagnosis of osteosarcoma and is considered the final diagnostic
procedure. A biopsy that it inadequately performed will lead to failure or delay in diagnosis and
there by alter  the prognosis of the patient  and also may lead to amputation  due to inability  to
attempt a limb salvage operation.  All patients with bone lesions that are suspicious of osteosarcoma
must undergo a biopsy.  Lesions which appear benign clinically and radio logically need not need a
biopsy.  On the other hand lesions that appear malignant, aggressive or with doubtful appearance
need a biopsy.  Biopsy must be done in a center with the adequate reliable diagnostic facilities
where the patient must be able to undergo operative treatment and other modalities of treatment
required for his condition. It was found that biopsies done at smaller ill equipped centers had a
complication  in  15.9%  of  patients,  diagnostic  errors  in  13.5  of  patients  and  3%  of  patients
underwent amputation which were deemed unnecessary.(46,47) It was the same in a study done by
the same author in 1982 and it did not change considerably when he studied it again in 1996.
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The location of the biopsy tract has also become important with the increased number of
limb salvage operations that are being performed as it requires the excision of the biopsy tract in-
toto with the tumour to avoid recurrence of the tumour due to spillage at the biopsy site.  A well
performed biopsy helps to know the histological type of the tumour and the grade of the tumour.
Earlier open biopsies were performed and spillage of the tumour did not matter as amputation was
the  treatment  of  choice.   Nowadays  per-cutaneous  biopsies  with  core-cut  needle  are  being
performed and it decreases the incision size and the tumour spillage without decreasing the biopsy
yield. Core needle biopsy is done using a 14-gauge needle. It was found that core of maximum
length of 20 mm, was more than 90% accurate in differentiating malignant from benign lesions.(48)
In case of lesions where the diagnosis in inconclusive or in lesions where the core biopsy does not
correlate with radiologic and clinical findings an open biopsy is advised.  While performing a open
biosy the incision must be made longitudinally and must be preferably performed by the surgeon
performing the definitive procedure.  If the biopsy requires a window to be made in the bony cortex
it must be made in a oblong shape longitudinally as this helps to prevent pathological fractures
following the biopsy.  A study which compared the residual bone strength following biopsy showed
that  a  rectangular  hole  with  square  corners  or  rectangular  hole  with  rounded  corners  had  less
residual bone strength to resist fractures in comparison to a oblong hole with rounded end.(49)
Fine needle aspiration cytology has also been used in the diagnosis of osteosarcoma and it has been
found  to  be  effective  and  quick  method  of  diagnosing  osteosarcoma.(50)  But  it  requires  the
expertise  of  a  pathologist  well  experienced  in  fine  needle  aspiration  cytology.  Another  study
showed that fine needle aspiration cytology can obviate the need for open biopsy in patient with
high-grade osteosarcoma demonstrating typical radiological features.(51)
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Incision for open biopsy
Drain site following open biopsy
Staging of Osteosarcoma:
Staging  of  osteosarcoma  involves  the  staging  of  the  primary  tumour  and  the  systemic
staging.  Local staging of the tumour is done with the help of plain radiographs of the involved
region in two planes.  MRI helps to look at the soft tissue involvement and extent and also the bone
marrow involvement and extent. 
Systemic staging of osteosarcoma involves evaluation of the lung and skeleton for any metastases
and most metastases occur in the lung or in the bone. Spiral CT done during a single breath-hold
with a collimation of less than 5 mm helps to rule in or out lung metastasis.  Tc99m diphosphate
bone scan with the help of plain radiographs helps to rule out bony metastasis. 
Two  main  systems  of  staging  are  under  use  for  staging  of  Osteosarcoma.  One  is  the
Musculoskeletal society scoring system, adopted from the Enneking staging system and the other is
the  American  Joint  committee  on cancer  staging system.   The Musculoskeletal  tumour  society
staging system has been widely used for many years and it classically divides a malignancy into two
grades ie. high grade and low grade and whether the tumour is contained within the compartment or
whether the tumour has breached the compartment.
Enneking staging system for Primary Malignant Tumors of Bone
Stage Tumor Metastases Grade
IA T1 M0 G1
IB T2 M0 G1
IIA T1 M0 G2
IIB T2 M0 G2
III T1 or T2 M1 G1 or G2
T1 – Tumour is intra-compartmental
T2 – Tumour is extra-compartmental
M0 – No regional or distant metastasis
M1 – Regional or distal metastasis
G1 – Low grade
G2 – High grade
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The second staging system is the AJCC staging system or the TNM staging system.  The
following table elaborates the AJCC staging system.
American  Joint  Committee  on  Cancer  Staging  System  for  Primary  Malignant
Tumors of Bone for Those Tumors Diagnosed on or After January 1, 2003
Stage Tumor Lymph Node Metastases Grade
IA T1 N0 M0 G1 or G2
IB T2 N0 M0 G1 or G2
IIA T1 N0 M0 G3 or G4
IIB T2 N0 M0 G3 or G4
III T3 N0 M0 Any G
IVA Any T N0 M1a Any G
IVB Any T N1 Any M Any G
IVB Any T Any N M1b Any G
Tx - primary tumor cannot be assessed M0 - no distant metastasis
T0 - no evidence of primary tumor M1 - distant metastasis
T1 - tumor 8 cm or less in greatest dimension M1a - lung
T2 - tumor more than 8 cm in greatest dimension M1b - other distant sites
T3 - discontinuous tumors in the primary Bone Gx - grade cannot be assessed
Nx - regional lymph nodes not assessed G1 - well differentiated (low grade)
N0 - no regional lymph node metastases G2 - moderately differentiated (low grade)
N1 - regional lymph node metastasis G3 - poorly differentiated high grade)
Mx - distant metastasis cannot be assessed G4 - undifferentiated (high grade)
Treatment of Osteosarcoma:
The  treatment  of  Osteosarcoma  has  evolved  over  the  past  3  decades.  It  requires  a
multidisciplinary treatment model. It has been noticed that 89-90% of the patients with apparent
localized disease eventually  develop metastases predominantly in the lungs when chemotherapy is
not administered.   If  chemotherapy is  not instituted early on in the course of the disease these
patients  will  die  of  metastases.   Randomized  trails  done showed the  improved survival  due to
chemotherapy.
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Current treatment regimens include the following modalities 
1. Surgery
2. Chemotherapy
3. Radiotherapy
This multidisciplinary treatment  has improved the survival  among patient  with osteosarcoma to
about 60-70%.
The objective of operative management of osteosarcoma is complete removal of the tumour.
Operative management must aim to get at-least a wide margin during the operation. A wide margin
implies that the tumour and the biopsy tract must be removed with cuff of healthy tissue that is not
violated. 
Enneking criteria for surgical margins in musculoskeletal Tumors(52)
Margin Dissection
Intralesional Within the lesion
Marginal Through the pseudo-capsule or reactive tissue
Wide
Lesion (including biopsy scar), pseudo-capsule
and/or reactive zone, and an unviolated cuff of
normal tissue completely surrounding the mass
removed as a single block
Radical
Entire  anatomic  compartment  containing  the
tumor removed as one block
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Earlier amputation was the most common operative procedure done for osteosarcoma. But
with  improved  expertise  and  prosthesis  limb  sparing  operations  are  being  performed  more
commonly.  These  limb  sparing  operations  have  been  supported  by  advances  in  biomedical
engineering, imaging techniques with improved understanding of neoadjuvant chemotherapy. 
Various techniques have been used to reconstruct the limb following the tumour excision. Some of
them are 
1. Turn-up Plasty(53,54)
2. Endoprosthetic reconstruction 
3. Allograft reconstruction
4. Van Nes rotationplasty
Though various advances have been made in the surgical management of Osteosarcoma recurrence
of the tumour still continues to be a dreaded complication. Due to the various complication that
occur after operation these extensive operations must be attempted by a surgeon who is aware of the
various surgical techniques and is capable of implementing them for the appropriate patient.
Amputations: 
Currently amputations are employed only for those patients with significant neurovascular
infiltration or poor function of the distal extremity. Other indications include failed limb salvage
attempts, recurrent local recurrence of the tumour. Contamination of the soft tissue associated with
large hematomas is also considered an indication for amputation. 
Tumors involving the knee joint the which require a limb ablation procedure require a above
knee amputation or a hip dis-articulation procedure. The ideal optimal level as described for a above
knee amputation is considered at a level 15 cm above the knee joint line or 25 cm distal to the
greater trochanter.(55) The patient undergoing amputation generally has extensive disease and will
require complex bony and soft tissue resection. In such complex tumour resections this may not
always be possible and the stump might be much shorter and such patients would benefit from a hip
38
dis-articulation. 
Van nes rotationplasty is another alternative for preserving as much function as possible in
patients with distal femur osteosarcoma.(56)  This is done in skeletally immature individuals. This
procedure helps to get a functional limb that will act as a Below knee stump. Here the femoral
resection is  done as proximal as possible and the disease free tibia is rotated by 180 degree and it
functions  as the new knee joint.(57) It  has bee found that  the functional  results  following this
procedure are adequate and there have no adverse psychological outcomes. 
Limb salvage procedures:
Many recent studies show that limb-preserving operations are preferred to limb ablations
operations.    In  a multi-centric  study among 227 patient  who underwent  either  a limb salvage
procedure,  above  knee  amputation  or  hip  disarticulation  it  has  been  shown  that  limb-salvage
procedures do not compromise the disease free interval or the long term survival of the patients.
(58)
An important factor while attempting limb salvage operations is the adequacy of surgical
margins.   It  is  considered  that  in  case  of  high-grade  tumors  a  wide  margin  would  achieve
satisfactory local control in 95% of the patients. Sluga et al showed that in patient in whom wide or
radical margins can be achieved there was no significant difference in outcome between amputation
and limb preserving operations.(59)
Limb-preserving operations can be broadly classified as
1. Joint preserving - Arthroplasty
2. Joint ablating - Arthrodesis
Arthrodesis is usually achieved using allografts and vascularised autografts. It provides a
durable,  stable  reconstruction  of  the limb postoperatively  and is  resistant  to  the physical  stress
during the routine day to day activities. Moreover it is usually a one time procedure and does not
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require any further procedures once the bone unites. But it has its limitations due to its changes in
gait, sitting and also due the increased stress on the spine and hip. 
On the other hand joint preserving operations are done using a allograft or a endoprosthesis.
Structural  cadaveric  allografts  are  used  for  reconstruction.  Re-implantation  of  the  autoclaved
resected bone has also been reported.(60,61)  Allografts are associated with high complication rate
and significant morbidity. 
The common complication associated with allografts are non union, post operative infection
and secondary fractures. These complications have been noted in almost half the patient undergoing
such procedures.
Micro-vascular free fibula grafts have also been used to reconstruct the bony defect.(62,63)
Endoprosthetic reconstruction is the most common joint preserving reconstruction following
a tumour resection operation. This is done with use of modular/custom made prosthesis. Earlier
custom made prosthesis lead to increased manufacturing delays and decreased flexibility during
operation. With the availability of modular prosthesis this disadvantage has been negated. 
The  joint  is  usually  a  rotating  hinge  and  gives  good  mobility  though  it  is  more  constrained
compared  to  a  normal  knee.  The  complication  associated  with  a  endoprosthetic  reconstruction
include excessive wear, loosening, knee stiffness and failure of the endoprosthesis. 
A newer development in a endoprosthetic reconstruction is the availability of expandable
endoprosthesis for patients with immature skeleton. This is useful when the growth plate is involved
or when the growth plate is resected along with the tumour. The usage of expandable prosthesis
helps to compensate the normal distal femoral growth of 1.6 cm per year. Thus it helps to prevent
gait  disturbances,  compensatory  scoliosis  and  low  back  pain.  Some  examples  are  the  Phenix
Growing Prosthesis (Phenix Medical, Paris, France) and Stanmore expandable prosthesis (Stanmore
Implants, Stanmore Middlesex, United Kingdom). (64,65)
Reconstruction of the patella tendon or the extensor mechanism is a challenging procedure
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following tumour resection.  Kendall et al showed by their functional analysis that compromised
extensor mechanism was the main deterrent in achieving adequate function after tumour resection
of the knee.(66)  In the study by Grimer et al the extension lag of 30° was noted.(67) Another study
showed a lag of 15.5° ± 7.6° at 12 months after reconstruction.(68) The proximal tibia being the
second most common site for bony tumors, resection of tumors with adequate surgical margins will
most often lead to sacrificing the tibial tuberosity and the patella tendon attachment.  Moreover
highest  rate  of  complications  following  limb  salvage  operations  is  noted  among  patients  with
tumors  of the proximal  tibia.  Various  techniques  have been described for  reconstruction  of the
extensor mechanism following mega-prosthetic replacement.  
Bickels et al. described a technique in which the patellar tendon remnant was attached to the
prosthesis with a Dacron tape which was reinforced by autologous bone graft.  This reconstruction
was covered by a gastronemius flap.(69)  Among the 55 patients studied 48 patient had a functional
outcome that was good to excellent, in 6 patients it was fair and outcome was poor in 1 patient.
Eight patients required procedures for secondary reinforcement of the patella tendon.
Titus  et  al.  reported  the  usage  of  a  method  of  protection  of  the  extensor  mechanism
reconstruction following the attachment of the patella tendon after proximal tibia resections.  In this
method  the  patella  tendon  was  attached  to  the  anterior  surface  of  the  proximal  aspect  of  the
prosthesis  with  sutures  without  the  use  of  any  additional  flaps.  This  reconstruction  was  then
protected by the use of a cerclage wire between the patella and the proximal aspect of the prosthesis
thereby protecting the repaired ligament. It was found that though wire breakage was noted in six of
the ten patients they persisted to have good functional outcome.(70)
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Various other methods done for the reconstruction of patellar tendon include Trevira tube
and flap, Gore-Tex tube and flap, ligament augmentation device and flap, quadriceps turn down and
flap. 
Radiotherapy:
Osteosarcoma  was  considered  a  radio-resistant  tumour  and  hence  radiotherapy  was  not
commonly  employed  in  the  treatment.   A study done by the  Cooperative  Osteosarcoma  Study
Groups showed that radiotherapy has an influence on local control when combined with surgery.
(71)  Another study done by the same group in patients with osteosarcoma of the pelvis showed that
the patient who underwent radiotherapy had better survival compared to those who did not.(72)
High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate has been used as a mode
of targeted radiotherapy in patients with osteosarcoma.(73)  But its role and its benefit in patients
with osteosarcoma is yet to be delineated.(74)
Chemotherapy:
Osteosarcoma is considered a systemic disease at diagnosing with microscopic metastases
occurring early on in the disease.  Chemotherapy has been well studied and has been proven to
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Extensor mechanism reconstruction following tumour resection and endoprosthesis
improve the survival of the patient in osteosarcoma. 
Chemotherapy in osteosarcoma can be broadly divided as
1. Adjuvant
2. Neoadjuvant
Both adjuvant and neoadjuvant chemotherapy has been found to improve the overall survival of the
patients with osteosarcoma.(75–77)
Various  agents  have  used  in  the  systemic  therapy  of  osteosarcoma.  Cisplatin,
doxorubicin,high-dose methotrexate with leukovorin-rescue and ifosfamide are commonly used in
the various regimens and are considered as the agents that are most active against osteosarcoma.
The ideal effective combination is yet to be defined.  Among the current protocols most of them
include  a  period  of  neoadjuvant  (preoperative)  chemotherapy  and  a  period  of  adjuvant
(postoperative) chemotherapy.  The addition of preoperative chemotherapy has not found to add any
survival benefit over postoperative chemotherapy alone.(78)  But the administration of preoperative
chemotherapy has become the standard protocol as it gives the following advantages:(79,80)
1. It provides better delineation of the tumour and hence better surgical margin
2. The percentage of tumour necrosis following neoadjuvant chemotherapy offers prognostic
information
3. It provides valuable time for planning for the definitive limb-preserving procedure
 Another  study  evaluated  the  effect  of  chemotherapy  alone  in  the  treatment  of
osteosarcoma.  But it  was found that  only 3 out of 31 patients  who underwent this  modality  of
treatment survived without recurrence of the disease.(81)
Treatment of relapse or primary metastatic disease:
Treatment of metastatic osteosarcoma can be broadly divided into curative and palliative.
Curative management  can be offered to patients  with primary metastatic osteosarcoma and it  is
similar to that of the treatment of localized disease. It has been found that when curative therapy is
43
administered to patients with primary metastatic disease 30-40% of them might become long term
survivors. (82,83)
Relapse of osteosarcoma is associated with poor prognosis with the survival rate less than
20%. But studies have shown that if surgical remission is achievable in patients with relapse more
than one third of these patients will survive more that 5 years.(84)
Second line chemotherapy is administered to patients who have a relapse of the disease or
occurrence  of  metastases  following  initial  treatment.   Various  agents  have  been  tried  but  the
outcome following relapse persists to be poor.  The common agents used are ifosfamide, high-dose
methotrexate, cyclophosphamide, etoposide  topotecan, gemcitabine, pirarubicin and docetaxel.(85)
He et al found that pirarubicin based therapy was as effective as gemcitabine-docetaxel with lesser
toxicity when administered as a second line treatment for osteosarcoma.(86) It has also been shown
that the use of chemotherapy prolonged the survival in patients with relapse of osteosarcoma.(87)
Supportive care:
With multi-modal therapy becoming the cornerstone of treatment of osteosarcoma adequate
supportive care is essential for a successful outcome. The various drugs used in chemotherapy can
be fatal unless the patient is carefully monitored. The use of  serotonin antagonists, dexamethasone
to control chemotherapy induced emesis, opioid for pain relief and hematopoietic growth factors for
severe  granulocytopenia  induced  by  chemotherapy  has  made  chemotherapy  must  safer  and
acceptable than it earlier was.
Follow-up:
Follow up of patient undergoing treatment for osteosarcoma is very essential.  A detailed
history and physical examination must be done at each visit with evaluation of the blood counts.
Chest X-ray must be done and if it is inconclusive or doubtful it must be followed up by a CT of the
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thorax.
 The following table summarizes the various investigations and the recommended time-line
for follow-up of patient treated for osteosarcoma :
Suggestions for follow-up investigations after multi-modal therapy for osteosarcoma
Time Tumor directed Late effects
Baseline X-ray chest and CT
Echo-cardiogram,  audiogram,  liver  and
kidney  function,  hepatitis  B/C  and  HIV
serology
X-ray and (CT)/MRI primary site
Years 1 and 2 X-ray chest every 6–12 weeks
X-ray primary site every 4 months
Echo-cardiogram  every  1–2  years,
audiogram,  liver  and  kidney  function
Audiogram and liver  function need not  be
repeated if normal at 1 year
Years 3 and 4 X-ray chest every 2–4 months Echo-cardiogram every 1–2 years
X-ray primary site every 4 months
Years 5–10
X-ray  chest  every  6  months
Some  groups  recommend  annual
radiographs of the primary site until
year 10
Echo-cardiogram every 2–4 years
Thereafter
(Few)  relapses  reported  as  late  as
two decades after treatment. Discuss
with  patient  whether  to  continue
chest X-ray every 6–12 months 
Echo-cardiogram every 2–4 years
Survival and outcomes:
The survival in osteosarcoma among patients has greatly improved with the initiation of the
multi-modal  therapy.   Before  the  onset  of  multidisciplinary  treatment  and  the  introduction  of
chemotherapy the overall  survival  of patients  with osteosarcoma at  2  years  was 15-20%.  The
outcome also varies when the patient with classical osteosarcoma and non classical osteosarcoma
are compared. Classical osteosarcoma generally carries a better prognosis at it generally presents
without metastasis at presentation and as it occurs in the younger age group. 
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Currently the survival of the patients with multi-modal therapy has increased to 60-70%.
Among the patients belonging to the age group above 40 years, who are more prone to non-classical
osteosarcoma, the five year survival rate was 46%.(88)
Among the patients with Pagets disease who develop Osteosarcoma the survival remains
poor.  Mankin et al. found that the survival among this subset of patients was only 14% at 2.5 years.
(87) 
Patella position:
Patella position is a important factor playing an important role in the normal functioning of
the knee joint.(90)  Various methods have been described to evaluate the patellar position.  Some of
them  are  Insall-Salvati  ratio,  Blackburne-peel  method,  Caton-Deschamps  ratio,  Labelle-Laurin
method  and Linclau method.  In a study done by Eugene et al. they found that the Blackburne-Peel
ration reproduced the patellar height index most consistently.(91)  They also noted that the values
did not change significantly between 30° to 50° of knee flexion.  Rogers et al found that using
Blackburne-peel method decreased the inter-observer variability compared to Insall-Salvati index in
patient who underwent total knee arthroplasty.(92) 
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Complications:
Limb-preserving  operations  are   associated   with  higher  risk  of   complications  when
compared  to  the  limb  ablation  procedures.(93)  The  complications  may  be  immediate  or  late
complications.  Immediate complications include wound dehiscence, wound necrosis, periprosthetic
hematoma,  persistent  wound  drainage  and  delayed  wound  healing.   The  common  delayed
complications noted are aseptic loosening, implant breakage, bushing failure, superficial and deep
infections, dislocation, and periprosthetic fracture.  These complications have been reported in as
much as 40% of the patients in a series of patient.(94)  About 29% of  patients had implant failure
and almost 13% of the patients developed infections.
Wound  infection  following  mega-prosthesis  is  a  well  known  complication.(95) The
extensive dissection involved especially with the removal of large tumors and the dead space left
behind after tumour resection with the  presence of a metallic implant might assist the formation of
bacterial bio-films leading to the occurrence of infections in patients undergoing tumour resection
and  mega-prosthesis.   The  incidence  of  wound  infection  following  limb  salvage  operations  is
reported  to  be  around  11%-20%  in  most  studies.(96–98) Among  the  patient  undergoing
endoprosthetic reconstruction wound infection have been found to be more in patients undergoing
proximal tibial resection compared to the distal femur resections..(99) Among the patient devolving
infection 37% to 87% of the patient ended up having an amputation.(97,98,100)
Local recurrence  of osteosarcoma has increased with the increased number of limb salvage
operations being performed. Limb salvage has become the standard of care for the patient with
osteosarcoma whenever it is possible.  Local recurrence following limb salvage operation has been
reported from 2..4% to 16%.(101–103)
Prognostic factors:
Various factors have been found to be helpful to prognosticate the outcome in patients with
osteosarcoma.   These include disease specific  factors and treatment  related factors.  The disease
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specific  factors  include  sex,  metastasis  at  presentation,  level  of  alkaline  phosphatase,  tumour
volume and treatment related factors include amount of tumour necrosis and surgical margins.(104)
Presence  or  absence  of  metastases  at  presentation  was  found  to  be  the  most  important
prognostic indicator in the survival of patients  with osteosarcoma as the presence of metastasis
decreased the overall survival significantly.(104–106)
Male sex was also found to have a poorer prognosis compared to their female counterparts.
(104)  In the study published by the Scandinavian sarcoma group male sex had a increased risk of
4.1 compared to the female counterparts.(105)
The level of alkaline phosphatase has been associated with prognosis of the patient with
osteosarcoma. Increased pretreatment level of alkaline phosphatase in patients with osteosarcoma is
associated with poor outcome and increase chance of recurrence compared to the patients whose
levels are normal.(43,107) Other studies did not show any association between the level of alkaline
phosphatase and prognosis.(75)
The  initial  tumour  volume  has  also  been  associated  with  outcome  of  patients  with
osteosarcoma.(108)  Patients  with  large  tumors  at  presentation  had  a  less  favorable  outcome.
Among the patients studied under Scandinavian sarcoma group tumour volume above 190 ml was
associated with poor outcome.(105)  Kim et al showed that a larger tumour was associated with
poor histological response and poor outcome.(108)  Kaste et al showed that absolute tumour volume
at  diagnosis  was  significantly  associated  with  event  free  survival  and over  all  survival  among
patients  with  non-metastatic  osteosarcoma.(109,110)  Another  study  showed  that  an  absolute
tumour volume of less than100 ml was associated with better outcomes.(111)
Histological grade of the osteosarcoma has also been found to have prognostic implications.
Most conventional osteosarcoma belong to high grade. Tumors with a low or intermediate grade
have been found to be associated with better event free survival, overall survival and decreased
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incidence of metastases.
Tumor necrosis following neoadjuvant  chemotherapy has been found to have significant
prognostic association.  As per Rosen et al.  the tumour is graded as four grades. Grade I and II
corresponded to poor histological response and grade III and IV corresponded to good histological
response.(112)  In another study done by Picci et al. a necrosis of greater than 80% was considered
as good, 50% - 80% was considered fair and a necrosis of less than 50% was considered poor.(113)
Rosen grades(114)
Grade Percentage of tumor necrosis
I Very little necrosis
II Necrosis more than 50%
III Necrosis more than 90%
IV No viable tumor cells seen
Poor histological response has been associated with decreased event free survival and decreased
overall survival among patients with osteosarcoma.(106,112,115)  Response to chemotherapy was
found to have the strongest association with local recurrence.
Surgical  margin has been found to have prognostic role in osteosarcoma. Earlier  studies
showed that surgical margins were associated with risk of local  recurrence and poor prognosis.
(104,115)  A study done by Kong et  al  showed that  marginal  or  intralesional  excision  was
associated with decreased metastases free survival.(116)  Local recurrence of the tumour has also
been related to the adequacy of the surgical margin.(117) A recent study evaluated the advantage
provided  by  amputation  in  patients  with  close  margins  and  poor  necrosis.  It  was  found  that
amputation did not offer any survival benefit in such patients though it offers a wide local clearance.
(118)
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METHODOLOGY
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Aims:
The aim of this study was to follow up patients with osteosarcoma of the distal femur and
proximal tibia  who underwent mega-prosthesis of the knee in our institution.
Objectives:
1) The main  objective  of  the  study was  to  evaluate  the  clinico-radiological  outcome in
among patients with osteosarcoma of  the distal femur or proximal tibia, who underwent tumour
excision and  mega-prosthesis of the knee in our institution between January 2010 and October
2014.
2) To evaluate  the relationship between tumour volume,  tumour grade.  tumour necrosis,
alkaline phosphatase levels and the prognosis among the patients with osteosarcoma of  the knee
who underwent tumour excision and  mega-prosthesis of the knee in our institution between January
2010 and October 2014.
3) To evaluate the patella position following tumour reconstruction and the effectiveness of
the simple method of reconstruction of the extensor mechanism.
Materials and methods:
This was a ambidirectional cohort study. We studied the patients who underwent tumour
excision and mega-prosthesis of the knee from January 2010 till October 2014.  There patients were
on follow up in the outpatient clinic following the operation. The hospital records of these patients
were accessed and they relevant  data  pertaining to the study were collected.  The patients  were
followed up until the latest follow up in the outpatient clinic or they were followed up until their
death.  The patients who did not come for follow up following the surgery and those who stopped
follow up after a certain period were contacted via the telephone calls from the numbers stored in
the hospital information system. Apart from the patients whose death was confirmed earlier via the
hospital record all patients were contacted via phone and survival or death was confirmed.  The
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time of  death of the patient  was also found out  from the  patients  records  or  from the patients
relatives during the phone call. 
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Treatment Protocol
Preoperative:
Detailed clinical examination
Blood investigations
Plain radiographs – two views
Biopsy
Chest X ray(CT thorax/PET imaging if required)
MRI(For all patients)
Bone scan
Multidisciplinary Tumour Board(MDTB) – Decision on preop Chemo/RT
Neoadjuvant Chemotheraphy(if decided by the MDTB)
Repeat radiographs of the lesion
Surgery
Postoperative:
Knee ROM in the immediate post operative period as wound heals
Multidisciplinary Tumour Board(MDTB) – Decision on postop Chemo/RT
Adjuvant Chemotheraphy(as decided by the MDTB)
Radiotheraphy(as decided by the MDTB)
Followup protocol
Every 3 months in the first year
Every 4 months in the second year
Every 6 months for the next 2 years
Yearly follow up for atleast 10 years
Investigation done at followup:
Detailed history and clincal examination
Plain radiographs – two views
Chest X ray
Ultrasound(if required)
CT Thorax – If there is any doubt on Chest – Xray
Bone scan if suspision of bony metastasis
Special investigation: Echo, Audiogram(if required)
Indication for CT Thorax:
     Suspicious nodue on Chest X ray
Indication for PET imaging:
     Non specific pain with normal plain radiographs and bone scan
Inclusion criteria:
All  patient  who  underwent  tumor  excision  and  mega-prosthesis  of  the   knee   for
osteosarcoma of the distal femur or proximal tibia in our institution  from January 2010 till October
2014 as decided in the multidisciplinary tumor board meeting.
Exclusion criteria:
1. Presence of metastasis .
2. Patient with infected or fungating tumour
3. Any large tumour requiring amputation 
4. Osteosarcoma of the fibula
5. Not a definite diagnosis of osteosarcoma
6. Large tumours requiring a total femur or tibia replacement 
Sample size:
Using the incidence of local recurrence from the previous dissertation, 9% the sample size
was(Confidence level 95% and  margin of error at  5%)
N=1.96  2   x 0.09 x 0.91 = 125
0.102
Defining variables:
Tumour necrosis was classified as per the criteria by Rosen et al and then sub-classified as
per the description of Bacci et al.(112,114) As from the previous studies tumour necrosis of >90%
was considered as good and a tumour necrosis of <90% was considered as poor. Hence all patient
with tumour necrosis of <90% were considered to have a poor necrosis and the patients who had
tumour necrosis above 90% were classified as good necrosis.
Histological the grade of the tumour were classified based on histological criteria.
Lesions with cellular atypia, marked vascularity increased mitosis and increased necrosis associated
with poor differentiation are found have a higher likelihood of metastases.(119).  The American
joint  committee  on  cancer  classified  osteosarcoma  into  four,  grade  1  is  moderately  well
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differentiated,  grade  2  is  poorly  differentiated,  grade  3  is  poorly  differentiated,  grade  4  is
undifferentiated.  Though the tumour is classified as four grades they are essentially grouped into
two grades. Tumors belonging to grade 1 and 2 are considered as low grade and tumors belonging
to grade 3 and 4 are considered as high grade.  At times when the tumor cannot be fully classifies as
either high grade or low grade a new group is added and the tumour is classified as intermediate
grade.(119)
Histological grading
Osteosarcoma Grade Histological grade
Low-grade Grade 1 and 2
High-grade Grade 3 and 4
Intermediate grade Tumors between high and low grade
The grade of the tumour was tumour and percentage of the tumour necrosis were retrieved
from the histopathological reports of the patients stored in the electronic records of the patients. But
the sub-types could not be retrieved as the reporting in out institution did not routinely involve
reporting of the histological sub-type. Tumor margins were also  retrieved from the histopathology
reports of the patient who were enrolled in the study from the electronic records of the respective
patients.  All patient had tumour margins that were reported in the histopathology reports. If all
margins were negative it was classified as clear margins and the positivity or involvement of any
one of the tumour margins was classified as  involved tumour margin. 
Tumor volume has been associated with prognosis in patients with osteosarcoma. In
a study done at St. Jude Children’s Research Hospital,  Tennessee, it  was showed that a tumour
volume more than  150 cm3 was associated with increased risk of death compared to patient with
lesser tumour volumes.(109)  Tumor length, breadth and depth were calculated from the MRI of the 
patients by using the Centricity software(GE Healthcare)..
We measured the tumour volume by the ellipsoid formula(120,121)
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Measurement of the tumour width and depth in a distal femur osteosarcoma
(Female 17 yrs)
Measurement of the tumour length in a osteosarcoma of proximal tibia(Male, 17 yrs)
         Level of alkaline phosphatase among children and adolescents.   Source: Turan S, Topcu B, Gökçe I, Güran T, Atay Z, Omar A, et al. 
Serum Alkaline Phosphatase Levels in Healthy Children and Evaluation of Alkaline Phosphatasez-scores in Different Types of Rickets. 
J Clin Res Pediatr Endocrinol. 2011 Mar;3(1):7–11. 
Tumour Volume =  4 π/3(abc )
= (4 π/3) X 0.5 X ATL X 0.5 X ATW X 0.5 X ATD
= 0.52 X ATL X ATW X ATD
In the above formula a, b, c are the radii of the length, width and height of the tumour.
Tumor depth is calculated as the depth of the tumor extending from the anterior  extent of the tumor
to the posterior extent of the tumor on the MRI.
Alkaline phosphatase values for the patients included in out study were collected
form the patient record. The level of alkaline phosphatase before the onset of treatment ie. before
chemotherapy or surgical excision of the tumour was found.  Though studies have shown that the
level of alkaline phosphatase at diagnosis correlates with the outcome and the risk of metastases,
other studies have shown that the level of alkaline phosphatase may not be of any value.  With this
controversy over the value of alkaline phosphatase we  sought to find if there is any relation with
the outcome in the patients included in the study.  Another issue with alkaline phosphatase was the
normal increase that is noted during the pubertal growth spurt.  A study published earlier classified
the mean values and the normal ranges of alkaline phosphatase in the respective age groups among
children  and  adolescents.(122)  In  the  adults  an  alkaline  phosphatase  level  of  40-125U/L was
considered as normal. Using the values published we classified the patients into those with high
alkaline phosphatase and those with normal levels.
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The Blackburne-Peel index is the ration between length of the line projected from the distal part of
the joint surface of the patella anteriorly to the tibial plateau surface and the length of the articular
surface of the patella.(123)  The radiographs of all patients include in the study were accessed via
the hospital information system. All radiographs were reviewed and  all the patients who had the
radiographs taken with the knee at 30° of flexion were included in the study. The distance between
the upper surface of the anterior tibial  component was measured and the length of the articular
surface was measured.  These measurements were made on the radiographs with the help of the
Centricity software(GE Healthcare)  
A
Blackburne-peel ration of less than 0.8 was considered as patella infera, 0.8-1 was considered as
normal and a ratio of greater than 1 was considered was patella alta.(90)
Blackburne-peel ratio
Type of patella Range
Patella infera <0.8
Patella norma 0.8-1
Patella alta >1
We  at  our  hospital  used  the  simple  method  of  reconstruction  of  the  patella  tendon
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reconstruction as described by Titus et al.(70)  Wire breakage was a expected occurrence in the
patients undergoing this procedure.  Even in the study published by Titus et al six out of  10 patients
developed wire breakage though it did not affect the function. (70) 
This method of reconstruction was routinely done in the patients who underwent resection
of the tumour of the proximal tibia.   We evaluated the radiographs at follow up to look at the
breakage of the wire and the approximate time period when the wire breakage occurred.
The  occurrence  of  local  recurrence,  bony  metastasis,  wound  infection,  need  for  wound
suturing, time of wire breakage were also collected from the records of the patient.
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Brocken cerclage wire as seen on the followup radiograph  of the patient
Statistical Analysis:
Data  entry  was  done  with  the  help  of  LibreOffice  Spreadsheet  V  3.5(The  Document
Foundation) and all statistical analysis were done with the help of SPSS(IBM SPSS v20). Survival
and local recurrence were found out for patients included in our study. Kaplan- Meier method was
used for calculating the overall survival and  effect of other factors on time to local recurrence and
the significance of the other factors affecting local recurrence.
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Pre-op, Intraop and Post-op images of a patient
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Clinical photographs: DS, 18, F
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Preoperative radiographs
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Postoperative radiographs
AT, 14 yrs, F, Proximal tibia
64
Results
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Results:
From the year January 2010 to October a total of forty one patients who were diagnosed
with osteosarcoma of the distal femur or proximal tibia and underwent mega-prosthesis of the knee
were found to be eligible to be enrolled into the study, as per the inclusion and exclusion criteria.
The average age of the patient included in the study was 24 years(11-66 years). Out of the
patients 41 patient 21 (51.2% ) patients were below or at 19 years of age, another 15 (36.4%) were
between 19 and 40 years and  5(12.2) patients were above 40 years. 
As shown in the chart above most patients in our group fell in the age group between 10-25 years of
age. 
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 There were 24 males and 17 females among the 41 patients included in this study. 
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On plotting the age group of the patients in relation to the sex of the patients the peak in the
number of female patient occurred earlier than the peak in the number of the female patients.
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The minimum follow up of the patients was 3 months and the maximum follow up of the
patient included was 67 months.  The mean follow up of the patients included in the study was 31
months. 
The distal femur was the site for osteosarcoma in 25  of the patients and the proximal tibia
was the site for osteosarcoma in the rest  patients. 
 Tumour  grade  was  not  reported  for  two patients.  Most  patients  fell  in  the  high  grade
group(80%) compared to the intermediate grade(15%  and low grade(3%).
Only 36 patients recruited in this study received preoperative chemotherapy. The others did
not  receive  preoperative  chemotherapy.  Among  the  36  patients  who  received  neoadjuvant
chemotherapy tumour necrosis was found to be good(more than 90%) in only 4 patients and the rest
32 patients had a poor necrosis or a necrosis percentage less that 90%. 
Tumour volume was less than  400 cm3 in 30 patients and the in 11 patients it was
more than 400 cm3. Tumour volume more than 400 cm3 was found to be associated with decreased
survival and this difference was significant(p=0.009).  The mean survival in patients with tumor
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volume more than 400 cm3 was 24.8 months compared to 55 months among patients who have
tumor volume of less than 400 cm3. 
Tumor depth was found to be less than 7 cm in 30 patients  and more than 7 cm in 11
patients. Tumor depth more than 7 cm was found to be associated with decreased overall survival
and this difference was statistically significant (p = 0.009). The mean survival among the patients
with tumor depth more than 7 cm was 23.7 months compared to 56.2 months in patients whose
tumor depth was less than 7 cm. 
Alkaline phosphatase levels before the onset of treatment were not available for 3 patients.
25 patients had normal alkaline phosphatase levels and 13 patients had high alkaline phosphatase
levels. Higher levels of alkaline phosphatase was associated with decreased over all survival. The
mean survival in patients with normal alkaline phosphatase was 52 months  compared to 36 months
among the patients with normal alkaline phosphatase levels. But this difference was not statistically
significant.(p=0.092)
Tumor margins were positive for 12 patients and the remaining 29 patients had margins that
were clear of the tumor. Out of the 12 patient one patient had three margins involved,  5 patients
had  two margins that were involved and six patients had a single margin that was involved. But
there was no significant association with overall survival among the patients studied.
Seven patients who were included in this study developed local recurrence. In one patient
the local  recurrence  developed within  a  month.  In  the  other  patient  3  patients  developed local
recurrence  at  3  months  after  surgery,  2  patients  developed  local  recurrence  at  5  months  after
surgery. One patient developed local recurrence 35 months after surgery.  Local recurrence was
associated with poor survival and this association was statistically significant.(p=0.005)
Local  recurrence  was  significantly  lower  in  patient  s  who  received  postoperative  radiotherapy
compared to the  patients who did not under go radiotherapy.
Eight patients had wound dehiscence and skin necrosis requiring re-suturing in the operation
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theater. Out of the 8 patients 6 of them underwent re-suturing once and the 2 of them required re-
suturing twice.
The complications noted were amputation,  wound infection,  aseptic loosing, knee
stiffness and implant failure.
8 patient among the patients included in our study eventually required amputation.  One
patient in our study developed a avascular limb following a extensive tumor resection and vascular
reconstruction and hence underwent amputation. The other reasons for amputation were infection in
5 patients  and local  recurrence  in  2 patients.  There was a  association  between amputation  and
tumour necrosis, alkaline phosphatase level at diagnosis and tumour margins. But this association
was not statistically significant. Tumour volume of more than 400 ml was associated with increased
risk of amputation and this association was statistically significant.(p=0.049)
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Amputation
Tumour grade No Yes Total P value
High 24 8 32
0.777
Intermediate 5 1 6
Low 1 0 1
Total 30 9 39
Amputation
Tumour necrosis No Yes Total P value
Poor 24 8 32
0.345Good 4 0 4
Total 28 8 36
Amputation
Margin No Yes Total P value
Clear 23 6 29
0.53Positive 9 3 12
Total 32 9 41
76
Infection Local recurrence Vascular repair failure
0
1
2
3
4
5
6
5
2
1
Causes for amputation
Reason for amputation
N
um
be
r o
f p
at
ie
nt
s
Amputation
Tumour volume No Yes Total P value
<400 26 4 30
0.049>400 6 5 11
Total 32 9 41
Washout, flap and antibiotics Amputation
0
1
2
3
4
5
6
4
5
Wound infection and treatment
Mode of treatment
N
um
be
r o
f p
at
ie
nt
s
 Wound  infection  was  noted  in  10  patients.  5  patients  who  developed  wound  infection
underwent amputation and the other five patients were treated with wound washout, muscle flap
and IV antibiotics.
Revision of  mega-prosthesis was done in 4 patients included our study. One patient developed
aseptic  loosening  and hence underwent revision and the others had implant breakage and hence
required revision.
Out of the 41 patients who underwent mega prosthesis 3 patients developed significant knee
stiffness postoperative and hence required manipulation under anesthesia. All of them attained good
flexion following the manipulation under anesthesia but one patient later developed lung metastasis
and died.
One  patient  developed  chemotherapy  induced  Myelodysplastic  syndrome  at  one  year
following operation and was on treatment for the same.
Out of the 41 patients studied 12 patients had died and 24 patients were alive. 5 patients
were lost to follow up.  The mean survival time was 49 months. Overall survival was significantly
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associated with local recurrence, development of metastasis, tumor volume more than 400 ml and
tumour depth more than 7 cm. 
Though  the  sex,  site  of  the  tumour,  level  of  alkaline  phosphatase  at  diagnosis,  tumour
necrosis  showed association with survival the association was not statistically significant.
Among our patients 11 patient developed metastasis. 10 patients developed lung metastasis and one
patient developed bony metastasis. Among those who developed metastasis the patient with bony
metastasis and 4 patients with lung metastasis died. 3 patients with lung metastasis are alive and are
on follow-up. All the patients who are alive were recently diagnosed to have metastatic disease.
Local recurrence was noted in 7 of the 41 patients included in the study. Local recurrence
was significantly associated with tumor volume more than 400 ml(p=0.006), tumour depth more
than 7cm(p=0.006) and radiotherapy(0.005). Tumour volume and tumour depth increased the risk of
local recurrence while radiotherapy was associated with decreased local recurrence.
The was no significant statistically significant association between tumour necrosis, margin,
level of alkaline phosphatase and local recurrence of the tumour.
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The time to local recurrence was also significantly associated with tumour volume(0.001),
tumour depth(p=0.001) and the development of metastatic disease(0.025).
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Blackburne-peel ratio was calculated for 22 patients for whom radiographs were available at
30 degree flexion. 18 patients did not have radiographs at 30 degree and hence were excluded. The
Blackburne-peel ratio was significantly associated with lag noticed postoperatively.(p=0.017) But it
did not have any significant effect on the flexion of the patients. 
There  were  16  patients  in  whom the  method  of  extensor  mechanism  reconstruction  as
described by Titus et was was done. The wire broke in 5 and in 11 it remained intact at the last
follow-up.  Among   the  11  patients  with  intact  wires  only  one  patient  had  a  intact  wire  still
functioning at follow up. All other patients with intact wires either underwent amputation or died
before the wire broke. The presence of absence of a intact wire did not affect the extension lag in
the knee. 
The volume of the tumour resected did not have any statistically significant effect on flexion
or extension lag noticed in the patients. 
The length of resection on the tibia and femur also did not show any association with knee
flexion or extension lag postoperatively.
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Discussion:
Osteosarcoma though known for 2 centuries is associated with significant morbidity and
mortality.  Though multi-modal treatment has improved the survival and outcome for the patients
with osteosarcoma survival rates have not significantly improved over the last two decades. In our
country, during the 1990s,  before mulitmodal  treatment  ie.  limb salvage surgery, chemotherapy,
radiotherapy was introduced the only treatment available offered was amputation. The western data
available with such an approach, in the prechemotheraphy, preradiotherapy and preprosthesis time,
had a survival of 20%. Hence any improvement in survival is an improvement in prognosis. In our
institution tumour staging is done with the help of Chest x ray and bone scan due to financial
constraints.  CT  Thorax  is  a  confirmatory  investigation  for  decision  between  limb-salvage.
amputation or no surgery. We also have had patients in whom PET scan and CT scan have missed
metastasis.  Generally amputation is offered only as a curative operation in non-metastatic lesions
and   for better quality of life in  patients with metastatic disease. Patients with metastatic disease
who sustain a pathological fracture are offered palliative surgery. 
In our study we noted a overall survival rate of 67% among the patient undergoing multi-
modal therapy for osteosarcoma of the proximal tibia or distal femur that are treated with tumour
excision and mega-prosthesis. Survival rates of osteosarcoma have been reported from 58 -70%.
(1,2,112) and our study also notes survival rates as has been reported in other studies. 
We also noted that tumour volume was associated with survival. Various studies have noted 
different volumes and tried to find any correlation that might be present. Various cut off that have 
bee used include 150mll(112), 190 ml(105) and 150cm3(121). We found out, among our patients a cut 
off of 400cm3 was significantly associated with overall survival, local recurrence and time to local 
recurrence.  We also found that in our patients the tumour volume was significantly high.  11 (27%) 
patients in this study had a tumour volume greater than 400cm3.  In an earlier study done by Kaste 
et al a tumour depth of 5 cm was found to be associated with over all survival. In our study we 
94
noted a tumour depth of 7 cm to be significantly associated with survival.(121)
Many earlier studies have shown that a positive tumour margin was associated with tumour
recurrence  and  poor  survival.(104,116) Some  studies  found  that  positive  tumour  margin  was
associated increased risk of local recurrence.(117,124) Another study noted that amputation did not
affect the outcomes in patient who were found to have positive surgical margins.(118) Thus the role
of margins though well proven in earlier is still being evaluated for better understanding of its role.
In our  study we did not  find  any association  between tumour margin  and over  all  survival  or
recurrence of the tumour. In our study we had 12 patients who had positive margins. 
Tumour  necrosis  after  chemotherapy  has  been found to  have  prognostic  significance  in
many studies and it use as to tool to prognosticate outcome in osteosarcoma.(101,104,112,125)
But in our study we found that though it was associated with survival the association did not reach
statistical significance. This may be because of the small number of patients we had while dividing
into subgroups. Another factor is that most of the tumours were large in size.  27  patients had
tumour volume that was more that 200 cm3  and among them 11 of them had volume more than
400cm3.  It  has  been  shown  in  earlier  studies  that  tumour  volume  by  itself  is  an  independent
prognostic  factor  and  this  might  have  played  a  confounding  the  role  with  regards  to  tumour
necrosis.
Histological  grade  of  the  tumour  has  been  associated  with  survival  of  the  patients  in
osteosarcoma. Traditionally grade I and II are considered to be low grade and grade III and IV are
considered as high-grade. The overall survival rate for low grade osteosarcoma is 90%(126,127)
while  the  overall  survival  rate  for  high  grade  osteosarcoma  is  about  60-70%(1). Low  grade
osteosarcoma are associated with better outcomes than high grade sarcoma as noted in previous
studies. Among our  patient we did notice an association between survival and tumour grade with
the lower grades having better survival. But this association did not reach statistical significance. 
High levels of alkaline phosphatase have been associated with poorer outcomes in patient in
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earlier studies.(128,129) They have also been shown to have prognostic significance. In our patients
higher  level  of  alkaline  phosphatase  was  associated  with  decreased  over  all  survival.  But  this
association did not reach statistical significance.
Though osteosarcoma was considered to be a radio-resistant  tumour earlier  studies have
shown that radiotherapy, when employed along with surgery and chemotherapy, decreased the local
recurrence  and  gave  better  local  control  of  the  tumour.(71) In  our  study  we  also  noted  that
radiotherapy was associated with decreased local recurrence. There was significant reduction in the
number of local recurrences in the patients who under radiotherapy compared to those who did not.
But radiotherapy after surgery is  associated with  increased wound complications.  In our study
though radiotherapy was associated with increased wound complication,  the association did not
reach statistical significance.
The mean time for the recurrence of osteosarcoma has been noted to be 11 months.(130)
Late recurrence of osteosarcoma has been noted in other studies even after 20 years.(131) In our
study we noted that the mean time for local recurrence was 7.5 months. Except for one patient who
had a recurrence at 3 years all other patients had local recurrence in the first year in our study. This
is in accordance with the notion that most recurrences in osteosarcoma occur in the first year after
surgery.(132) We also noted that tumour volume, tumour depth and metastases were found to have
significant associated with time to local recurrence of the tumour.
The median time for metastases was reported to be 10 months by Aljubran et al.(133) In  our
patients we found that the median time to metastasis was 8 months(range 5-26 months). 
We also noted that  8 patients included in our study required re-suturing of the wound and 2
of them required re-suturing twice. The indication was necrosis of the wound edges in all the cases.
This might be due to large size of the tumours that were associated with those patients. Though re-
suturing  was  associated  with  higher  tumour  volumes  the  association  did  not  reach  statistical
significance.
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Conclusion:
The over all survival of our patients was 67%. Local recurrence of associated with decreased
over all survival among our patients. Local recurrence was noted in 20% of our patients. Survival
rate and local recurrence were better than what we expected as we considered the large size of the
tumour. We found that tumour volume and tumour depth are associated with local recurrence among
patients and have significant effect on the over all survival of the tumour.  This is well known in
earlier studies that have been published.  Moreover patients come with larger tumour volumes due
to the delay in seeking medical attention and the difficulty in accessing tertiary care centers which
offer  multi  modal  treatment  for  osteosarcoma  as  most  of  the  secondary  care  centers  offer
amputation as the primary treatment option. 
Though osteosarcoma is the commonest primary true bone malignancy, mainly affecting the
children and adolescents the outcome for osteosarcoma has not significantly improved over the last
decade in the western countries. 
1) Our study shows comparable clinico-radiological  results  with regard to  local  recurrence and
survival when compared with the available published literature.
2)Local recurrence of the tumour, tumour volume and tumour depth, radiotherapy, metastasis are
significantly associated with over all survival. Tumour volume, tumour depth and radiotherapy are
significantly associated with local recurrence. Though the site of tumour and tumour necrosis were
associated with over all survival the association did not reach statistical significance.
3)The position of the patella as measured by Blackburne-peel ratio was significantly associated with
knee lag noted postoperaviely.
4)We did not find any association between tumour grade and survival or local recurrence. It might
be due to reason that 80% of the tumours were high grade tumours.
The introduction of adjuvant chemotherapy increased the survival dramatically but after that
the survival of osteosarcoma has plateaued.  This is not the case with developing countries as access
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to affordable healthcare is still a difficulty.  Ours institution is the second tumour center and our
series  probable  has  the  largest  number  of  large  tumours  that  have  been  studied.  With  more
researchers studying the genetic basis of osteosarcoma and the molecular pathogenesis, this might
help in making the next big leap in tackling osteosarcoma and improving the survival. 
Limitations:
In our study the number of patients were small and the number became even smaller when
they were divided into subgroups for analysis. Moreover large number of patients included in our
study  had  larger  tumour  volume  that  might  introduce  a  bias.  Most  of  the  data  was  collected
retrospectively from the inpatient and outpatient records and also from the electronic database. We
could not find the survival of all the patients as 5 patients were lost to followup.
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